Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision — free guideline decision tool
This tool combines PI-RADS, PSA density, and DRE for biopsy/follow-up triage, then after diagnosis gives NCCN risk stratification and active-surveillance/surgery/radiotherapy + ADT/chemotherapy principles.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Common questions
What does Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision do?
Use to decide biopsy versus follow-up (1–2 mostly follow-up, 3 by PSAD, 4–5 biopsy) and, once ISUP/stage are known, to stratify risk and outline treatment.
How is the result calculated?
PI-RADS + PSAD (threshold 0.15) → biopsy decision. ISUP grade + PSA band + cT → NCCN risk group (low/favorable-int/unfavorable-int/high/very-high) → surveillance vs RP vs EBRT + ADT, with chemotherapy/ARPI for advanced disease.
Is this a substitute for clinical judgement?
No. All results are decision-support only, for licensed clinicians. They must be individualized to the whole patient and the latest guideline version.
Run Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision now
This tool combines PI-RADS, PSA density, and DRE for biopsy/follow-up triage, then after diagnosis gives NCCN risk stratification and active-surveillance/surgery/radiotherapy + ADT/chemotherapy principles.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.